Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 292.12 Billion | 274.03 Billion | 250.07 Billion | 235.16 Billion | 241.92 Billion | 260.01 Billion |
| Cost of Revenue | 146.23 Billion | 156.29 Billion | 132.23 Billion | 124.64 Billion | 121.21 Billion | 117.23 Billion |
| Gross Profit | 145.89 Billion | 117.73 Billion | 117.83 Billion | 110.51 Billion | 120.71 Billion | 142.77 Billion |
| Operating Expenses | 126.39 Billion | 94.55 Billion | 83.92 Billion | 78.27 Billion | 75.81 Billion | 83.23 Billion |
| Selling, General and Administrative Expenses | 41.46 Billion | 42.71 Billion | 34.76 Billion | 33.02 Billion | 28.59 Billion | 39.78 Billion |
| Research and Development Expenses | 4.16 Billion | 3.65 Billion | 2.58 Billion | 1.5 Billion | 2.6 Billion | 3.74 Billion |
| Other Expenses | 50.56 Billion | 48.18 Billion | 46.57 Billion | 43.74 Billion | 44.61 Billion | 90.75 Million |
| Cost and Expenses | 272.63 Billion | 250.84 Billion | 216.15 Billion | 202.92 Billion | 197.02 Billion | 200.47 Billion |
| Operating Income | 20.48 Billion | 23.18 Billion | 33.91 Billion | 32.24 Billion | 22.2 Billion | 59.54 Billion |
| Interest Expense | 4.42 Billion | 1.76 Billion | 141.92 Million | 41.74 Million | 24.14 Million | 34.88 Million |
| Income Tax Expense | -3.34 Billion | 3.32 Billion | 6.5 Billion | 4.95 Billion | 9.99 Billion | 34.52 Billion |
| Earnings before Tax | 15.59 Billion | 25.22 Billion | 34.91 Billion | 32.82 Billion | 21.87 Billion | 60.05 Billion |
| Net Income | 18.9 Billion | 21.89 Billion | 28.4 Billion | 27.87 Billion | 11.88 Billion | 25.52 Billion |
| Earnings Per Share Basic | 1460.00 | 1727.82 | 2308.75 | 2266.09 | 917.07 | 2075.29 |
| Earnings Per Share Diluted | 1459.45 | 1727.82 | 2308.75 | 2266.09 | 917.07 | 2075.29 |
| Weighted Average Shares Outstanding | 12.94 Million | 12.67 Million | 12.3 Million | 12.3 Million | 12.3 Million | 12.3 Million |
| Weighted Average Shares Outstanding (Diluted) | 12.95 Million | 12.67 Million | 12.3 Million | 12.3 Million | 12.3 Million | 12.3 Million |
| Gross Margin | 0.50 | 0.43 | 0.47 | 0.47 | 0.50 | 0.55 |
| EBIT Margin | 0.13 | 0.12 | 0.17 | 0.17 | 0.12 | 0.26 |
| Profit Margin | 0.06 | 0.08 | 0.11 | 0.12 | 0.05 | 0.10 |
| EBITDA | 36.63 Billion | 33 Billion | 41.27 Billion | 39.36 Billion | 27.57 Billion | 66.34 Billion |
| Earnings Before Tax Margin | 0.07 | 0.08 | 0.14 | 0.14 | 0.09 | 0.23 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 70.75 Billion | 72.55 Billion | 292.12 Billion | 77.19 Billion | 71.82 Billion | 73.08 Billion |
| Cost of Revenue | 36.8 Billion | 36.33 Billion | 146.23 Billion | 38.66 Billion | 42.42 Billion | 45.64 Billion |
| Gross Profit | 33.95 Billion | 36.22 Billion | 145.89 Billion | 38.52 Billion | 29.39 Billion | 27.43 Billion |
| Operating Expenses | 26.58 Billion | 30.74 Billion | 126.39 Billion | 31.28 Billion | -24.23 Billion | -25.48 Billion |
| Selling, General and Administrative Expenses | 19.77 Billion | 21.61 Billion | - | 22.81 Billion | 24.23 Billion | 25.48 Billion |
| Research and Development Expenses | 6.42 Billion | 9.02 Billion | - | 8.26 Billion | 10.1 Billion | 9.59 Billion |
| Other Expenses | -388.11 Million | -104.07 Million | -639.2 Million | -203.14 Million | -48.47 Billion | -50.97 Billion |
| Cost and Expenses | 63.39 Billion | 67.07 Billion | 272.63 Billion | 69.94 Billion | 42.42 Billion | 45.64 Billion |
| Operating Income | 7.36 Billion | 5.48 Billion | 19.49 Billion | 7.24 Billion | 5.15 Billion | 1.95 Billion |
| Interest Expense | 1.2 Billion | 1.26 Billion | 4.42 Billion | 1.38 Billion | 1.1 Billion | 1.13 Billion |
| Income Tax Expense | 4.73 Billion | 1.07 Billion | -3.34 Billion | -1.89 Billion | 765.4 Million | -592.22 Million |
| Earnings before Tax | 29.56 Billion | 4.21 Billion | 15.59 Billion | 5.51 Billion | 3.9 Billion | 220.31 Million |
| Net Income | 24.79 Billion | 3.09 Billion | 18.9 Billion | 7.37 Billion | 3.14 Billion | 812.53 Million |
| Earnings Per Share Basic | 1947.17 | 242.58 | - | 577.37 | 245.57 | 62.40 |
| Earnings Per Share Diluted | 1947.17 | 242.58 | - | 577.37 | 245.57 | 62.40 |
| Weighted Average Shares Outstanding | 12.73 Million | 12.77 Million | 12.95 Million | 12.77 Million | 12.79 Million | 13.02 Million |
| Weighted Average Shares Outstanding (Diluted) | 12.73 Million | 12.77 Million | 12.95 Million | 12.77 Million | 12.79 Million | 13.02 Million |
| Gross Margin | 0.48 | 0.50 | 0.50 | 0.50 | 0.41 | 0.38 |
| EBIT Margin | 0.16 | 0.14 | - | 0.15 | 0.41 | 0.38 |
| Profit Margin | 0.35 | 0.04 | 0.06 | 0.10 | 0.04 | 0.01 |
| EBITDA | 11.2 Billion | 10.34 Billion | - | 11.62 Billion | 29.39 Billion | 27.43 Billion |
| Earnings Before Tax Margin | 0.10 | 0.08 | 0.07 | 0.09 | 0.07 | 0.03 |
MPHASIS
1817
ALLWF
600012
002324
LIBERTSHOE